Healthy Stock Picks (@Healthstockpick) header
Healthy Stock Picks (@Healthstockpick) profile picture

20 years of investing. Now covering the Healthcare sector, predominantly micro to mid-caps. All my writing is free, no pay-walls.

Global
Joined February 2024
Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)Photo by Healthy Stock Picks (@Healthstockpick)
Healthcare portfolio out-performing my wider portfolio, mostly thanks to Modern Dental and more recently Envista, still in total with several stocks in serious drawdowns I'm up less than 1% YTD. As you can see Medtech sector has been brutal in 2026, down 6%.
1
1
14
3,462
Healthy Stock Picks retweeted
November edition. Now you have something interesting to read instead of Alibaba and Tencent earnings. Inside: -On China markets vs World -On earnings visibility vs multiples -On sector fundamentals: 💩 vs 💎 -On me navigating the bear -On Kistler paired with slow roasted piquillo peppers pandawatch88.substack.com/p/…
5
6
1
49
5,812
Interesting development today in Akeso $9926.HK - what has turned into a blockbuster drug for lungcancer in China did not get approved by FDA. Big Pharma last few years have all turned to Chinese biotech as their opportunity to develop innovative drugs cheaper.
2
8
1,179
Another perspective on this
$SMMT I think ivonescimab marks a historic inflection point in global pharmaceutical innovation. Historically, breakthrough drugs were first approved in the US, while Chinese patients often had to wait years due to regulatory and reimbursement delays. Now, the roles are beginning to reverse. Ivonescimab, a first-in-class PD-1 × VEGF bispecific with remarkable clinical efficacy, has been available to Chinese patients since: May 2024: Post-TKI EGFR-mutant NSCLC April 2025: 1L PD-L1+ NSCLC August 2026: 1L squamous NSCLC + chemo Meanwhile, American patients are still waiting. And this is no longer an isolated case. Cadonilimab, sac-TMT, iza-bren and satri-cel are all examples of innovative oncology therapies reaching Chinese patients ahead of their American counterparts. We may be entering a new era in which American patients have to wait years to access some of the world's best cancer therapies. Maybe it's time to get our Chinese visas ready, just in case we need to travel there for better treatment options someday. How can we avoid this from happening? @FDA ?
1
363
The largest investment opportunity right now that I can see is the very strange sell-off in Medtech companies. It feels like tech investors are just selling off medtech to buy Semi/AI-tech related plays. It's trading at a historical unprecedented discount to the market:
2
497
Healthy Stock Picks retweeted
After listening to the FDA’s full presentation of the new @FDA guidelines for individualized genome editing products I can’t emphasise enough just how much of a game-changer they really are - for Gene Editing-based treatments such as Prime Editing $PRME and Base Editing $BEAM! IMO the key difference between the current regulatory framework for approving new genetic treatments and the FDA’s new proposed guidelines is that different variants of the same gene will no longer be considered by the FDA as a new clinical indication - which requires a new clinical trail, but instead all that it would require from Beam or Prime in order to receive a regulatory approval would be to submit a BLA supplement which is huge! As of now these new FDA guidelines will be relevant only for individualized Gene Editing products meaning therapies that use Gene Editing technology to correct specific, patient-unique disease-causing genetic variants and which intended to prevent, treat, or cure a monogenic disease or condition caused by known pathogenic gene variants, where all product variants in the BLA are designed to achieve the same editing outcome. This is absolutely tremendous and super exciting for the entire Gene Editing field!
It seems the FDA has finally decided to cross the Rubicon and published a new and revolutionary regulatory framework which aims to expedite the regulatory approval process of new Gene Editing-based treatments - such as $BEAM Base Editing and $PRME Prime Editing. These new proposed guidelines are the pinnacle of a regulatory process which began with a Cell and Gene Therapy Roundtable - held last year by FDA former commissioner @MartyMakary and the former director of the FDA’s Center for Biologics Evaluation and Research (CBER) @VPrasadMDMPH, in which researchers, industry leaders and scientists set together with FDA officials to bring new ideas to the table. During this fascinating meeting Prof. @davidrliu from @Harvard & the @broadinstitute and most importantly the inventor of Base Editing and Prime Editing has made a closing statement which really caught my attention: “It’s not only about treating 1,000 rare disease patients but about building a modular system that turns rare disease treatment into a national engine for therapeutic innovation and which will secure America’s leadership in Genetic medicine for the foreseeable future.” It seems that finally Prof Liu’s call was answered!
4
23
6
104
19,383
Healthy Stock Picks retweeted
24
94
4
2,871
102,808
What started for me with an email to $OSSD CEO asking who their largest competitor was, I started to look at $KURN Over time I realized Kuros is winning I sold my OSSD shares and held KURN. I think by now we can already conclude the race as over, perhaps $BONEX can put up a fight
1
1
12
1,657
Will be hard for $BONEX.ST to keep up, revenue:
2
317
Healthy Stock Picks retweeted
A few charts on China real estate prices, rents, sales. For tier 1 cities, we are now back to 2016 prices, 10 year roundtrip (and counting). Comparison: --In the US, prices bottomed in 2012, back to 2004 levels, 8 years roundtrip. --In Europe, bubble chad places like Spain, prices bottomed in 2015 back to 2002 levels, 13 years. Time to start bottoming? Or 3 more years to go? Who knows. HK turned already last year. Funny (or sad): --Spain, 10 years after bottoming, is now on the opposite side, complaining about high prices (fair complain, they are high vs salaries). The eternal pendulum. --Those that complain ask for more new housing to bring down prices. They don't have memory of what made prices come down in 2007, for how long, and why nobody could buy for the next 10 years despite lower prices. Careful what you wish for. --In China prices only started to come down when financing to developers was cut and they stopped building houses. --People tell you supply/demand charts work. The craving to explain the world with two variables. They don't. Only at extremes. Demand drives the market, not supply. Demand depends on expectations and FOMO, not on families calculating how new build inventories will impact prices. Same with share prices. --aaaanyway. Same story, every time.
8
9
1
75
7,732
After getting much more insight into the working hours and night shifts doctors are pulling, I have a lot of feelings on this topic. 1. It is not OK that doctors have to work 30h+ hour shifts with no to little sleep. 2. Is not OK to be treated for something serious by said doctor
" I am so out of time." A surgeons warning.
2
5
1,200
Why is this normalized in most countries? I really don’t understand, educate more doctors reduce working hours and wages, create work life balance, which countries have actually implemented this?
1
238
Interesting times for contrarians, I have loaded up on a few already, one already doubled from the bottom, volatility is insanely high in something that should be stable predictable non/low-cyclical business
Large Cap Med-Tech trades at its lowest multiple in over a decade. It also trades at its lowest relative P/E to S&P 500 since the Dot Com Bubble. Wild times in MedTech land.
3
1
11
2,907
As we can see these dislocations only happen when the market gets totally sucked into a hype in another sector like 1998-2000 and the past two years with AI
2
313
Replying to @leevalueroach
What about your job?
12
1
132
4,061
Healthy Stock Picks retweeted
I was having dinner last night with a friend working in the chicken industry and I learned something that blew my mind. Where do chicken farmers get their chickens? Most of us would say "from their existing chickens obviously, they breed and lay eggs." That's what I thought too, but turns out I was dead wrong. The reality is that the immense majority of meat chicken farmers in the world get their chickens from one of 2 companies: Cobb-Vantress, owned by Tyson Foods, or Aviagen, controlled by Germany's EW Group (the Wesjohann family). They have a concept specific to the industry called grandparent stock: what you buy from these 2 companies is - essentially - a bunch of chickens with planned obsolescence. The way it works is that each company keeps "pure" bloodlines on its own farms. Let's label them A, B, C and D. Those are the crown jewels - these companies' IP - and they never leave the building. What they sell you are the "grandparents": chicks from those four lines, but each line in only one sex. You get A roosters but no A hens, B hens but no B roosters, C roosters but no C hens, D hens but no D roosters. Which means you can never breed more A, B, C or D birds yourself. What you can do is cross them. A roosters with B hens give you the fathers, C roosters with D hens give you the mothers - these are the "parents". The parents then give you the chickens that actually end up on our plates, slaughtered at around 6 weeks. And that's the end of the road. If you tried breeding those chickens, their chicks would be a complete genetic lottery: still chickens, sure, but without the genetic properties that make them commercially viable. They'd grow slower and less evenly, you'd have to sell them for way more than your competitors, and your business would be dead. So you have to go back to Cobb or Aviagen for new grandparents. Forever. Why buy grandparents at all, and raise 2 generations just to sell the third? The answer is scale. If you buy say 100 grandparents, each of them gives you around 50 parents, and each parent hen then gives you around 150 chicks: from those 100 grandparents, you have yourself some 600,000 chickens whose meat you can sell. It makes no sense for these 2 companies to sell the final chickens directly. They'd have to hatch tens of billions of chicks a year and ship them all over the world. Much easier to simply sell the grandparents and let farmers do the multiplying and pay for the farms, the feed and the labor. And, you knew this was coming, there is also a China angle here: as you can imagine, China isn't too pleased to be dependent on foreign companies for such a basic food item as chicken. So China did what China does best: long-term planning. The Ministry of Agriculture and Rural Affairs launched a plan for "national broiler genetic improvement" (2021-2035), which aims for domestically bred breeds to make up at least 60% of the domestic market by 2035 (globaltimes.cn/page/202307/1…). And, of course, they're ahead of the plan. As of 2025, homegrown breeds held more than 30% of the market: halfway to the 2035 goal in just four years (agripost.cn/2026/08/17/china…). Can you escape all this as a consumer? Sure, you can buy organic or Label Rouge chicken, from slower-growing breeds raised for at least 81 days instead of 6 weeks, for two to three times the price. Except, plot twist: the genetics behind most of those slow-growing birds come from a French company called Hubbard... which has belonged to Aviagen since 2018 (euromeatnews.com/aviagen-ann…)😅 And even if you could truly escape, you wouldn't want everyone to: we'd need vast new swathes of farmland, both for the chickens and their feed. Ironically, advocating for organic free-range chicken for everyone is one of the worst positions one can take for the planet's resources. If you want to minimize your environmental footprint, the counterintuitive answer is to buy the cheapest supermarket chicken - or eat less meat, of course. As my friend was saying last night, you may not like the way this industry works but, at the end of the day, it's what puts affordable protein on the plates of billions of people, using proportionally fewer resources than any other way of raising chicken.
214
1,519
227
6,327
488,404
For various reasons, AI, life, mood I have not posted for a year, but now Im back with an idea, hope you enjoy it, as always no paywalls, link in my profile - Ak Medical $1789.HK
3
34
2,642
Many good points on HK and inequality. Sweden where I come from is very equal and few people has the need to show wealth through luxury goods
Americans take note 👀 The gambling junkies are expanding EVERYWHERE as your currency becomes shit everything downstream will go to shit
2
711
Coming to Hong Kong before year end?
I CALLED IT. It's happening y'all. The singapore gov has launched a pilot programme for a gov-run dating service. Looks like the pilot is currently restricted to just government workers for now.
1
504